Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

BackgroundAmong several treatment options for BRAF-mutant metastatic melanoma, a combination of BRAF inhibitor, MEK inhibitor, and anti-PDL1 antibody seems to be a new emergent approach recently registered in the Russian Federation. It is still not clear which patient population benefits more from t...

Full description

Bibliographic Details
Main Authors: Igor V. Samoylenko, Yulia M. Kolontareva, Ekaterina V. Kogay, Natalia V. Zhukova, Igor A. Utyashev, Mikhail E. Ivannikov, Konstantin V. Menshikov, Maxim V. Zinkevich, Kristina V. Orlova, Yulia V. Vakhabova, Mikhail V. Volkonsky, Natalia A. Beliaeva, Ivan I. Butkov, Elena V. Karabina, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Vitaliy D. Sychev, Oxana S. Cheplukhova, Vera V. Chernova, Alexandr N. Yurchenkov, Ksenia G. Babina, Nikita A. Savelov, Lev V. Demidov
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
metastatic melanoma
BRAF-mutant
triple combination
brain metastases
atezolizumab
vemurafenib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1395378/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1395378/full

Similar Items